H. Bruckner

Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome.

S. Itzkowitz, M. Tatematsu, J. Werther, 1994, British Journal of Cancer.

Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer.

E. Feuer, J. Holland, H. Bruckner, 1989, European journal of cancer & clinical oncology.

Prognostic factors: Cisplatin regimens for patients with ovarian cancer after failure of chemotherapy

E. Feuer, H. Bruckner, C. Cohen, 1987, Obstetrics and gynecology.

CEA Monitoring Among Patients in Multi‐institutional Adjuvant G.I. Therapy Protocols

S. Ellenberg, G. Steele, J. Horton, 1982, Annals of surgery.

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

D. Alberts, M. Buyse, L. Stewart, 1991, BMJ.

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

D. Alberts, W. Sauerbrei, M. Buyse, 1998, British Journal of Cancer.

Methyl-GAG in patients with malignant neoplasms: a phase I re-evaluation.

J. Holland, T. Ohnuma, R. Hart, 1982, Cancer treatment reports.

Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen

E. Feuer, J. Holland, H. Bruckner, 1989, Obstetrics and gynecology.